Rigel Pharmaceuticals
RIGL
112 hedge funds and large institutions have $176M invested in Rigel Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 10 closing their positions.
1,704% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $77K
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
53% more capital invested
Capital invested by funds: $115M → $176M (+$61.3M)
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
6% more funds holding
Funds holding: 106 → 112 (+6)
0.85% more ownership
Funds ownership: 6.09% → 6.94% (+0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$22.4M |
| 2 |
BlackRock
New York
|
+$802K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$466K |
| 4 |
Squarepoint
New York
|
+$331K |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.48M |
| 2 |
Millennium Management
New York
|
-$2.39M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$796K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$700K |
| 5 |
Two Sigma Advisers
New York
|
-$381K |
RIGL Hedge Fund Activity: Q4 2023 in Review
112 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2023, worth a combined $176M — up 53% from $115M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RIGL positions and 10 closed out — a net gain of 6 holders — while 38 added to existing stakes and 28 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $22.4M. The largest seller was Soleus Capital Management, cutting an estimated $5.48M.
- 112 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2023, up from 106 in Q3 2023.
- Funds reported $176M of Rigel Pharmaceuticals stock for Q4 2023, up 53% quarter-over-quarter.
- 16 funds opened new Rigel Pharmaceuticals positions in Q4 2023 and 10 closed out, a net change of +6 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $22.4M added.
- The largest Rigel Pharmaceuticals seller in Q4 2023 was Soleus Capital Management, an estimated $5.48M sold.
Based on aggregated 13F filings for Q4 2023.